유전체학 시장 규모, 점유율, 동향 및 예측 : 구성요소, 용도, 기술, 최종사용자, 지역별(2026-2034년)

The global genomics market size was valued at USD 43.3 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 127.2 Billion by 2034, exhibiting a CAGR of 12.26% from 2026-2034. North America currently dominates the market, holding a market share of 39.2% in 2025. The region benefits from substantial government investment in genomic research programs, a well-established healthcare and life sciences infrastructure, and the widespread integration of next-generation sequencing technologies into clinical diagnostics and precision medicine, along with strong biopharmaceutical research and development (R&D) activities, all contributing to the genomics market share.

The rising prevalence of chronic and genetic disorders worldwide is a significant factor propelling the growth of the genomics market. The growing adoption of precision medicine approaches, which rely on genomic data to tailor treatments to individual patient profiles, is further accelerating the demand for advanced genomic tools and services. Additionally, the declining cost of genome sequencing, driven by continuous technological advancements in next-generation sequencing platforms, is making genomic analysis more accessible across research institutions, hospitals, and diagnostic laboratories globally. The expanding applications of genomics in oncology, rare disease diagnostics, pharmacogenomics, and reproductive health are creating diverse revenue streams for market participants.

The United States is establishing itself as a major contributor to the global genomics market, supported by advanced healthcare infrastructure, strong diagnostic capabilities, and a dense network of academic medical centers engaged in leading genomic research. Federal funding continues to play a critical role in expanding precision medicine and population sequencing initiatives, strengthening integration of genomics into routine clinical care. This commitment is illustrated by the 2025 launch of BEACONS by Mass General Brigham and its partners, supported by a USD 14.4 Million NIH award, which planned to enroll up to 30,000 newborns across as many as 10 states to evaluate the feasibility and scalability of incorporating whole genome sequencing into public health newborn screening. Through such initiatives, the United States continues to advance clinical adoption models and reinforce its leadership position in the genomics market.

GENOMICS MARKET TRENDS:

Integration of AI in Genomic Drug Development

The growing application of AI in genomic analysis is accelerating drug discovery efficiency and improving target validation processes across the pharmaceutical sector. Companies are increasingly adopting AI driven platforms to analyze large scale genetic datasets, prioritize therapeutic targets, and refine clinical development strategies with greater precision. Reflecting this momentum, in 2025, Genomics launched Mystra, presented as the first AI enabled human genetics platform, built on more than 20,000 GWAS and trillions of integrated data points to enable rapid and scalable genetic analysis. Already adopted by major pharmaceutical companies under flexible service models, such platforms are strengthening R&D productivity and supporting higher clinical success rates, thereby driving market expansion.

Expansion of Advanced Genomic Diagnostic Infrastructure

The growing investment in specialized genomic centers across emerging economies is accelerating adoption of precision diagnostics and molecular testing services. Healthcare providers are strengthening laboratory capabilities, accreditation standards, and next generation sequencing capacity to meet the rising demand for oncology, reproductive health, neurology, and rare disease testing. Reflecting this trend, in 2026, Metropolis Healthcare launched its Centre of Genomics in India, integrating CAP accredited referral laboratories, multi-platform NGS systems, including Illumina's NovaSeq X Series, and multidisciplinary expertise to deliver more than 220 validated genomic tests, with plans to expand beyond 500. Such developments are enhancing access to high quality genomic services and contributing to the market growth.

Growing Demand for Integrated Multi-omic Analysis Solutions

The increasing demand for comprehensive molecular profiling is driving adoption of integrated multi-omic sequencing technologies within research and clinical settings. Researchers and clinicians seek solutions that capture both genetic variation and epigenetic modifications in a single workflow to improve biological interpretation and disease characterization. Reflecting this shift, in 2025, Illumina launched its 5-base solution, enabling simultaneous detection of genomic variants and DNA methylation from a single sample using proprietary chemistry and updated DRAGEN algorithms. Compatible with NovaSeq and NextSeq platforms, the commercially available kits enhance scalability and operational efficiency, supporting expanded use of combined genome and epigenome analysis in precision medicine research.

GENOMICS MARKET INDUSTRY SEGMENTATION:

Analysis by Component:

• Products
  • Instruments and Software
  • Consumables and Reagents
• Services
  • Core Genomics Services
  • NGS-Based Services
  • Biomarker Translation Services
  • Computational Services
  • Others

Products hold 62.4% of the market share. Genomics products encompass a wide range of instruments, software, consumables, and reagents that form the foundational infrastructure for genomic research and clinical diagnostics. Sustained demand for advanced sequencing platforms, high throughput analyzers, and optimized reagent kits is driving expansion in both mature and emerging markets. Laboratories are investing in integrated systems that improve workflow efficiency, data accuracy, and turnaround times while managing growing sample volumes. In addition, recurring demand for consumables and reagents provides a stable revenue base, reinforcing the commercial strength of the products segment. As genomic testing becomes more embedded in oncology, rare disease diagnostics, reproductive health, and population screening programs, continuous product innovation and portfolio upgrades remain central to maintaining operational scalability and supporting long term market growth.

Analysis by Application:

• Functional Genomics
• Epigenomics
• Biomarkers Discovery
• Pathway Analysis

Functional genomics accounts for 29.8% of the market share, reflecting its central role in elucidating gene functions, regulatory pathways, and molecular interactions that influence health and disease. By linking genomic variation to biological activity, this segment supports drug target discovery, gene and cell therapy development, and precise characterization of disease phenotypes at the molecular level. Research institutions and biopharmaceutical companies increasingly rely on functional assays, genome editing tools, and computational modelling to validate pathogenic variants and accelerate translational outcomes. This emphasis on application driven research was exemplified by Imperial College London's 2025 launch of the Functional Genomics Network, which integrated expertise in computational biology, clinical genetics, genome editing, and disease modelling to address bottlenecks in variant validation through coordinated pipelines and multidisciplinary collaboration. The genomics market forecast projections remain positive as continued investment in functional genomics research, translational networks, and variant validation capabilities drives sustained demand across clinical and therapeutic applications.

Analysis by Technology:

• Sequencing
• Microarray
• Polymerase Chain Reaction
• Nucleic Acid Extraction and Purification

Sequencing dominates the market, with a share of 44.6%. Sequencing technologies are the cornerstone of modern genomics, as it serves as the foundational technology for decoding nucleotide sequences across whole genomes, exomes, and targeted gene panels. Ongoing advancements in next generation sequencing platforms, marked by higher throughput, improved accuracy, and declining per sample costs, continue to strengthen adoption across clinical and research settings. Laboratories increasingly rely on sequencing for oncology profiling, rare disease diagnostics, and infectious disease monitoring, reinforcing its central role in modern molecular medicine. This leadership is reflected in 2025 developments, such as Gujarat becoming the first Indian state to initiate a large-scale genome sequencing project focused on tribal communities, aiming to address inherited disorders, including thalassemia and sickle cell anemia through genome decoding and development of targeted, low-cost screening and prenatal testing strategies. Such initiatives underscore sequencing's sustained dominance within the broader genomics market.

Analysis by End User:

• Research Centers
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotechnology companies represent the leading segment, with a market share of 38.7%. Pharmaceutical and biotechnology companies are among the most significant end users of genomics technologies, integrating genomic data throughout the drug discovery and development pipeline. These organizations leverage sequencing, genotyping, and bioinformatics tools to identify novel drug targets, stratify patient populations for clinical trials, and develop companion diagnostics that enable targeted therapeutic interventions. The increasing adoption of genomics-driven approaches in early-stage research and late-stage clinical development is strengthening the position of this end-user segment. For instance, in 2025, Helix announced it would present new population-scale genomic research at the ASHG 2025 Annual Meeting, showcasing insights generated from large-scale genomic data to support diagnostics and precision medicine applications. The growing pipeline of genomics-informed therapeutics, including gene therapies and RNA-based medicines, is further driving the demand for advanced genomic solutions within the pharmaceutical and biotechnology sectors.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for 39.2% of the share, enjoys the leading position in the market. The region benefits from a well-established healthcare ecosystem, extensive genomic testing infrastructure, strong public funding for biomedical research, and a high concentration of sequencing technology developers and molecular diagnostics companies. Continuous innovation in next generation sequencing platforms and precision medicine applications reinforces the region's competitive strength. Reflecting this commitment to long term sector development, in 2025, the Government of Canada launched the Canadian Genomics Strategy with an investment of USD 175.1 Million over seven years to accelerate commercialization and adoption of genomics across healthcare, agriculture, clean technology, and biosecurity, including personalized medicine and next generation vaccines. Led in collaboration with Genome Canada, the initiative was designed to enhance research translation, workforce development, and international competitiveness. These developments are expected to continue shaping favorable genomics market trends across North America, reinforcing the region's leadership in innovation, commercialization, and clinical adoption.

KEY REGIONAL TAKEAWAYS:

UNITED STATES GENOMICS MARKET ANALYSIS

The United States remains the largest national genomics market in North America, supported by substantial federal research funding, advanced healthcare systems, and a mature pharmaceutical and biotechnology industry that actively integrates sequencing into drug discovery and clinical practice. Leadership in genomic innovation is reinforced by the presence of major sequencing technology developers, leading academic research centers, and an expanding network of certified clinical genomics laboratories. The growing use of whole genome sequencing in neonatal screening, oncology diagnostics, and pharmacogenomics continues to widen commercial and clinical applications. Reflecting this sustained demand, in 2024 Complete Genomics opened a 10,115 square foot manufacturing facility at its San Jose headquarters, establishing its first United States based supply chain for DNBSEQ sequencing platforms and supporting research, engineering, and ISO compliant manufacturing to improve delivery timelines. Such investments strengthen domestic supply resilience while advancing the country's position in next generation sequencing technologies. Such investments strengthen domestic supply resilience while advancing the country's position in next generation sequencing technologies, offering a positive long term genomics market outlook.

EUROPE GENOMICS MARKET ANALYSIS

The Europe genomics market continues to evolve under the influence of large scale government funded sequencing programs and the steady integration of genomic testing into national healthcare systems. Public investment in population genomics, rare disease diagnostics, and cancer profiling is reinforcing the role of sequencing as a routine clinical tool rather than a purely research-based capability. This direction is illustrated by Genomics England's 2025 launch of the "Genomics, Healthcare and You" nationwide engagement program, designed to inform a future study that will sequence 150,000 adult genomes for preventive healthcare research, with consultations across the public, underrepresented communities, and healthcare professionals on pharmacogenomics, risk communication, and long-term data use during 2025 and 2026. Insights from this process will guide study design and digital infrastructure development, further embedding genomics within mainstream European healthcare delivery and supporting sustained genomics market growth across the region.

ASIA-PACIFIC GENOMICS MARKET ANALYSIS

The Asia Pacific region is emerging as a vital market for genomics, supported by expanding healthcare infrastructure, rising public funding for precision medicine initiatives, and the presence of cost competitive local sequencing providers that are improving access to advanced genomic technologies. Governments across the region are prioritizing national genome programs and translational research to strengthen population health management and biotechnology innovation. This momentum is reflected in a 2025 Memorandum of Understanding between Illumina and the Okinawa Institute of Science and Technology to accelerate genomics innovation in Japan under a One World, One Health approach, combining next generation sequencing technologies with interdisciplinary research to advance human, animal, and environmental health, including marine conservation through environmental DNA sequencing, as well as talent development and industry academia collaboration.

LATIN AMERICA GENOMICS MARKET ANALYSIS

The Latin America genomics market is growing steadily, supported by stronger government backing and cross border research partnerships aimed at strengthening regional genomic capabilities. The growing recognition of the value of genomic medicine in improving diagnosis, prevention, and population health outcomes is accelerating investment in sequencing infrastructure, national biobanks, and bioinformatics training. Reflecting this momentum, in 2025, Tecnologico de Monterrey announced that the oriGen Project achieved its target of collecting genetic samples from 100,000 individuals across 19 Mexican states, with exome sequencing planned for all participants and whole genome sequencing for 10,000 individuals, with initial results expected in 2026 to inform long term public health research.

MIDDLE EAST AND AFRICA GENOMICS MARKET ANALYSIS

The Middle East and Africa genomics market is at an early but promising stage of development, driven by increasing government investments in precision medicine infrastructure and population-scale genomic research programs. Several countries in the region are launching ambitious genome sequencing initiatives to address local healthcare challenges and build indigenous genomic databases. For instance, in 2025, a joint venture secured a contract from NUPCO in Saudi Arabia for large-scale genetic testing services, expanding precision medicine capabilities across 83 public hospitals throughout the kingdom. The growing adoption of genomic testing for infectious disease surveillance and cancer diagnostics is creating new opportunities for market expansion across the region.

COMPETITIVE LANDSCAPE:

The global genomics market is characterized by intense competition among established technology leaders, specialized diagnostic companies, and emerging innovators. Key market participants are pursuing strategies centered on technological differentiation, product portfolio expansion, and strategic partnerships to strengthen their competitive positions. Companies are investing substantially in R&D to advance sequencing accuracy, reduce per-genome costs, and develop integrated bioinformatics solutions that streamline laboratory workflows. The trend of consolidation through mergers and acquisitions (M&A) is enabling larger players to expand their capabilities across the genomics value chain, while strategic collaborations between technology providers and healthcare institutions are accelerating the clinical translation of genomic discoveries. The growing emphasis on AI-powered analytical tools, cloud-based data management platforms, and automated sample preparation systems reflects the evolving competitive dynamics within the industry.

The report provides a comprehensive analysis of the competitive landscape in the genomics market with detailed profiles of all major companies, including:

• 23andMe, Inc.
• Agilent Technologies, Inc.
• Bayer Aktiengesellschaft
• BGI Genomics Co. Ltd.
• Bio-RAD Laboratories Inc.
• Danaher Corporation
• Illumina Inc.
• Oxford Nanopore Technologies
• PerkinElmer Inc.
• Myriad Genetics Inc.
• Roche Holding AG
• Thermo Fisher Scientific Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the genomics market?

2. What is the future outlook of the genomics market?

3. What are the key factors driving the genomics market?

4. Which region accounts for the largest genomics market share?

5. Which are the leading companies in the global genomics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Genomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Component

• 6.1 Products
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Instruments and Software
    • 6.1.2.2 Consumables and Reagents
  • 6.1.3 Market Forecast
• 6.2 Services
  • 6.2.1 Market Trends
  • 6.2.2 Major Types
    • 6.2.2.1 Core Genomics Services
    • 6.2.2.2 NGS-Based Services
    • 6.2.2.3 Biomarker Translation Services
    • 6.2.2.4 Computational Services
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Functional Genomics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Epigenomics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Biomarkers Discovery
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pathway Analysis
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Sequencing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Microarray
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Polymerase Chain Reaction
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Nucleic Acid Extraction and Purification
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Research Centers
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hospitals and Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Pharmaceutical and Biotechnology Companies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 23andMe, Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Agilent Technologies, Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bayer Aktiengesellschaft
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 BGI Genomics Co. Ltd.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 Bio-RAD Laboratories Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Danaher Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Illumina Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Oxford Nanopore Technologies
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 PerkinElmer Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Myriad Genetics Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Roche Holding AG
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis